Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K4KM
|
|||
| Drug Name |
PMID29473428-Compound-60
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H31ClFN3O4
|
|||
| Canonical SMILES |
CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)OCC(=O)O)NC(=O)NC3=C(C=C(C=C3)Cl)F
|
|||
| InChI |
1S/C25H31ClFN3O4/c1-16(2)14-30(18-6-4-3-5-7-18)23-11-9-19(34-15-24(31)32)13-22(23)29-25(33)28-21-10-8-17(26)12-20(21)27/h8-13,16,18H,3-7,14-15H2,1-2H3,(H,31,32)(H2,28,29,33)
|
|||
| InChIKey |
TVQUEBMGNJZEOT-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target's Patent Info | [1] | |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.